Proactive Investors - Run By Investors For Investors

Advanced Oncotherapy looking at “disrupting” the cancer treatment market

Nicolas Serandour, chief operating officer (COO) and chief finance officer (CFO) Advanced Oncotherapy (LON:AVO), says the firm is looking at “disrupting the market” with its proton cancer treatment technology.

Serandour says: “We are in the business of treating cancer through radiotherapy but we are using – not X rays – but proton particles”.

The company is developing its cancer treating proton LIGHT proton therapy system, which accelerates protons to levels seen in previous machines but in a unit that is smaller and between a quarter and a fifth of the cost.

 “X rays are great at killing tumours but unfortunately because they are very light particles that are difficult to control, they also hit the tissue before and after the tumour,” he adds, noting that protons can attack the tumour without affecting the healthy tissue, but have, until now, been seen as too expensive by hospitals.

Meet Yellow Cake PLC, Avation PLC, Manolete Partners PLC and Crossword Cybersecurity Plc at our event, London , 05 September 2019. Register here »
View full AVO profile View Profile

Advanced Oncotherapy PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use